Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study.
Francesco SchettiniNavid SobhaniAnna IanzaTiziana TriulziAlfredo MolteniMaria Chiara LazzariCarla StrinaManuela MilaniSilvia Paola CoronaMarianna SiricoOttavia BernocchiFabiola GiudiciMaria Rosaria CappellettiEva CiruelosGuy JerusalemSherine LoiStephen B FoxDaniele GeneraliPublished in: Breast cancer research and treatment (2020)
Lymphocytes subpopulations, CECs and NLR could be interesting biomarkers predictive of response to everolimus-based regimens, potentially useful in daily clinical practice to select/monitor everolimus-based treatment in mBC. Further studies to confirm such hypotheses are warranted.